| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Young Ee Kwon, Jung Youl Park, Kyung Tai No, Jae Hong Shin, Sung Kwang Lee, Jae Soon Eun, Jae Heon Yang, Tae Yong Shin, Dae Keun Kim, Byung Sook Chae, Jae-Yoon Leem, Kuk Hwan Ki. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics. Bioorganic & medicinal chemistry. vol 15. issue 20. 2007-12-06. PMID:17681794. |
with the goal of developing alzheimer's disease therapeutics, we have designed and synthesized new piperidine derivatives having dual action of acetylcholinesterase (ache) and beta-amyloid peptide (abeta) aggregation inhibition. |
2007-12-06 |
2023-08-12 |
Not clear |
| Micheline Gagnon, Benoît Rive, Margaret Hux, Chantal Guilhaum. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 52. issue 8. 2007-12-06. PMID:17955915. |
to conduct a cost-effectiveness analysis comparing the addition of memantine to standard care (that is, without acetylcholinesterase inhibitors) with standard care alone in moderate-to-severe alzheimer disease (ad) in canada. |
2007-12-06 |
2023-08-12 |
Not clear |
| Christoph J G Lan. [Are anti-dementia drugs worthwhile?]. MMW Fortschritte der Medizin. vol 149 Suppl 3. 2007-11-19. PMID:17955784. |
the efficacy of the acetylcholinesterase inhibitors donepezil, galantamine and rivastigmine for alzheimer's disease is well-documented by a number of studies. |
2007-11-19 |
2023-08-12 |
Not clear |
| Toru Oda, Toshiaki Kume, Hiroshi Katsuki, Tetsuhiro Niidome, Hachiro Sugimoto, Akinori Akaik. Donepezil potentiates nerve growth factor-induced neurite outgrowth in PC12 cells. Journal of pharmacological sciences. vol 104. issue 4. 2007-11-07. PMID:17675796. |
donepezil is a potent and selective acetylcholinesterase inhibitor developed for the treatment of alzheimer's disease. |
2007-11-07 |
2023-08-12 |
Not clear |
| Stephen G Rice, Lee Nowak, Ellen G Duysen, Oksana Lockridge, Debomoy K Lahiri, Patricio F Reye. Neuropathological and immunochemical studies of brain parenchyma in acetylcholinesterase knockout mice: implications in Alzheimer's disease. Journal of Alzheimer's disease : JAD. vol 11. issue 4. 2007-11-02. PMID:17656828. |
neuropathological and immunochemical studies of brain parenchyma in acetylcholinesterase knockout mice: implications in alzheimer's disease. |
2007-11-02 |
2023-08-12 |
mouse |
| N Tabe. Acetylcholinesterase inhibitors for Alzheimer's disease: anti-inflammatories in acetylcholine clothing! Age and ageing. vol 35. issue 4. 2007-10-19. PMID:16788077. |
acetylcholinesterase inhibitors for alzheimer's disease: anti-inflammatories in acetylcholine clothing! |
2007-10-19 |
2023-08-12 |
Not clear |
| Jonathan Brouillette, Deborah Young, Matthew J During, Rémi Quirio. Hippocampal gene expression profiling reveals the possible involvement of Homer1 and GABA(B) receptors in scopolamine-induced amnesia. Journal of neurochemistry. vol 102. issue 6. 2007-10-19. PMID:17540011. |
scopolamine-treated rats are commonly used as a psychopharmacological model of memory dysfunction and have been extensively studied to establish the effectiveness of acetylcholinesterase inhibitors in the treatment of alzheimer's disease. |
2007-10-19 |
2023-08-12 |
human |
| F Jessen, W Maie. [A contribution to the current discussion on anti-dementia drugs in Germany]. Der Nervenarzt. vol 78. issue 5. 2007-10-18. PMID:17106726. |
in germany, the role of acetylcholinesterase inhibitors in the treatment of alzheimer's disease (ad) has become a topic of recent discussion. |
2007-10-18 |
2023-08-12 |
Not clear |
| S López-Pousa, J Garre-Olmo, J Vilalta-Franc. [Galanthamine versus donepezil in the treatment of Alzheimer's disease]. Revista de neurologia. vol 44. issue 11. 2007-10-10. PMID:17557224. |
to use comparative studies on the utilisation of the acetylcholinesterase inhibitors (ache), galanthamine and donepezil, to evaluate the effectiveness and tolerance of the two drugs in the treatment of the symptoms of alzheimer's disease (ad). |
2007-10-10 |
2023-08-12 |
Not clear |
| F Cortes, F Portet, J Touchon, B Vella. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials? The journal of nutrition, health & aging. vol 11. issue 4. 2007-10-09. PMID:17653493. |
six and 18-month changes in mild to moderate alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials? |
2007-10-09 |
2023-08-12 |
Not clear |
| Laure Ginestet, Juan E Ferrario, Rita Raisman-Vozari, Etienne C Hirsch, Thomas Debei. Donepezil induces a cholinergic sprouting in basocortical degeneration. Journal of neurochemistry. vol 102. issue 2. 2007-09-07. PMID:17394553. |
one of the few currently approved therapies for alzheimer's disease (ad) consists in the administration of acetylcholinesterase inhibitors, which enhances the lifetime of the neurotransmitter acetylcholine. |
2007-09-07 |
2023-08-12 |
rat |
| H Brodaty, P Sachdev, K Berman, L Gibson, N M Kemp, B Cullen, A Burn. Do extrapyramidal features in Alzheimer patients treated with acetylcholinesterase inhibitors predict disease progression? Aging & mental health. vol 11. issue 4. 2007-09-06. PMID:17612809. |
do extrapyramidal features in alzheimer patients treated with acetylcholinesterase inhibitors predict disease progression? |
2007-09-06 |
2023-08-12 |
Not clear |
| H Ollat, B Laurent, S Bakchine, B-F Michel, J Touchon, B Duboi. [Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease]. L'Encephale. vol 33. issue 2. 2007-09-06. PMID:17675917. |
[effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate alzheimer disease]. |
2007-09-06 |
2023-08-12 |
Not clear |
| H Ollat, B Laurent, S Bakchine, B-F Michel, J Touchon, B Duboi. [Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease]. L'Encephale. vol 33. issue 2. 2007-09-06. PMID:17675917. |
the efficacy of the inhibitors of acetylcholinesterase in alzheimer's disease (ad) is moderated and some patients do not respond to these treatments. |
2007-09-06 |
2023-08-12 |
Not clear |
| b' Zbyn\\xc4\\x95k Svoboda, Jaroslav Kv\\xc4\\x95tina, Josef Herink, Jir\\xc3\\xad Bajgar, Lucie Bartosov\\xc3\\xa1, Vladim\\xc3\\xadr Palicka, Pavel Zivn\\xc3\\xb. Galantamine antiacetylcholinesterase activity in rat brain influenced by L-carnitine. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. vol 149. issue 2. 2007-08-28. PMID:16601783.' |
galantamine (gal) is a selective, competitive and reversible acetylcholinesterase (ache) inhibitor, which increases the activity of the cholinergic system and hence gives rise to an improvement of cognitive functions in patients suffering from dementia of alzheimer type. |
2007-08-28 |
2023-08-12 |
rat |
| Francesca Mancini, Marina Naldi, Vanni Cavrini, Vincenza Andrisan. Multiwell fluorometric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors. Analytical and bioanalytical chemistry. vol 388. issue 5-6. 2007-08-20. PMID:17541560. |
therefore, in order to select new leads endowed with multifunctional activities, drugs for alzheimer's disease (ad) - potent acetylcholinesterase (ache) inhibitors - were tested for bace-1 inhibition using the proposed validated assays. |
2007-08-20 |
2023-08-12 |
Not clear |
| María-Salud García-Ayllón, María-Ximena Silveyra, Niels Andreasen, Stephen Brimijoin, Kaj Blennow, Javier Sáez-Valer. Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease. Journal of neurochemistry. vol 101. issue 6. 2007-08-16. PMID:17326766. |
cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with alzheimer's disease. |
2007-08-16 |
2023-08-12 |
Not clear |
| María-Salud García-Ayllón, María-Ximena Silveyra, Niels Andreasen, Stephen Brimijoin, Kaj Blennow, Javier Sáez-Valer. Cerebrospinal fluid acetylcholinesterase changes after treatment with donepezil in patients with Alzheimer's disease. Journal of neurochemistry. vol 101. issue 6. 2007-08-16. PMID:17326766. |
we analyzed whether donepezil differently influences acetylcholinesterase (ache) variants from cerebrospinal fluid (csf) in patients with alzheimer's disease (ad) after long-term treatment. |
2007-08-16 |
2023-08-12 |
Not clear |
| Iljung Lee, Yearn Seong Choe, Eun Kyoung Ryu, Byoung Wook Choi, Joon Young Choi, Yong Choi, Kyung-Han Lee, Byung-Tae Ki. Synthesis and evaluation of radioiodine-labelled CP-118,954 for the in-vivo imaging of acetylcholinesterase. Nuclear medicine communications. vol 28. issue 7. 2007-08-08. PMID:17538398. |
alzheimer's disease (ad) is characterized by reduced acetylcholinesterase (ache) activity in the post-mortem tissues of ad patients. |
2007-08-08 |
2023-08-12 |
Not clear |
| Richard Mahlberg, Sebastian Walther, Uta Eichmann, Ferenc Tracik, Dieter Kun. Effects of rivastigmine on actigraphically monitored motor activity in severe agitation related to Alzheimer's disease: a placebo-controlled pilot study. Archives of gerontology and geriatrics. vol 45. issue 1. 2007-08-02. PMID:16963137. |
acetylcholinesterase inhibitors (acheis) are effective in the treatment of cognitive symptoms in alzheimer's disease (ad). |
2007-08-02 |
2023-08-12 |
Not clear |